Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | MS & MOGAD: differences in response to immunomodulatory therapies

Hans Lassmann, MD, Medical University of Vienna, Vienna, Austria, discusses the similarities and differences between the pathology of multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD differs from MS by its clinical manifestation, course as well as by its response to treatment. For instance, the involvement of antibodies is more relevant in MOGAD than in MS, leading to major implications related to treatment responses since therapies targeting antibody production are much more effective in MOGAD than in MS. On the contrary, therapies targeting mostly inflammation show better results in MS. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.